CHICAGO: Novavax Inc stated on Thursday its coronavirus vaccine was 89.3% efficient in stopping COVID-19 in a trial carried out in the UK, and was almost as efficient in defending in opposition to the extra extremely contagious variant first found within the UK, in response to a preliminary evaluation.
Novavax stated the trial, which enrolled 15,000 folks aged 18 to 84, is predicted for use to use for regulatory evaluate in Britain, the European Union and different international locations. Some 27% of individuals within the trial are over 65.
The examine befell because the extra simply transmissible UK variant was circulating, and the preliminary evaluation suggests the vaccine was 85.6% efficient in opposition to this mutation, the U.S. firm introduced in a information launch. It didn’t present the examine information.
Novavax stated the trial, which enrolled 15,000 folks aged 18 to 84, is predicted for use to use for regulatory evaluate in Britain, the European Union and different international locations. Some 27% of individuals within the trial are over 65.
The examine befell because the extra simply transmissible UK variant was circulating, and the preliminary evaluation suggests the vaccine was 85.6% efficient in opposition to this mutation, the U.S. firm introduced in a information launch. It didn’t present the examine information.
